Le Lézard
Classified in: Health
Subject: LAW

Court to notify Washington residents who are, or were, patients of Virginia Mason Medical Center or Virginia Mason Health System or any of their affiliates and who used www.virginiamason.org or the MyVirginiaMason patient portal, that a class action lawsuit may affect their rights


SEATTLE, Sept. 11, 2023 /PRNewswire/ -- The lawsuit claims that Virginia Mason placed tracking pixels that transmit patients' personally identifiable information, their status as patients of Virginia Mason, and their communications with Virginia Mason to Facebook, Google, Signal, and The Trade Desk. The alleged communications included medical-related information and providers patients view on Virginia Mason's website, and when patients enter or exit the patient portal and request or set appointments. Plaintiffs assert claims for identity theft (RCW 9.35.020); breach of duty of confidentiality; invasion of privacy; violations of the Washington Consumer Protection Act (RCW 19.86.010, et seq.) and Washington Healthcare Information Act (RCW 70.2.005, et seq.); negligence; fraudulent concealment; and unjust enrichment. Defendants deny Plaintiffs' allegations.

The Court has ruled that this lawsuit is going forward as a class action. This means that the Plaintiffs will act as the Class Representatives, trying to get money damages and other relief for everyone who is a Class Member.

The Court decided that the Class includes all Washington residents who are, or were, patients of Virginia Mason Medical Center or Virginia Mason Health System or any of their affiliates and who exchanged communications at www.virginiamason.org or the MyVirginiaMason patient portal.

Class Members must choose whether to stay in the Class. If Class Members stay in the Class, and money or benefits are obtained for the Class, they will be notified about what they must do to share in any benefits for which they may be eligible. Class Members will be bound by all orders and judgments of the Court, whether favorable or not, and they won't be able to sue the Defendant for the claims at issue in this case. If Class Members want to stay in the Class, THEY DO NOT HAVE TO DO ANYTHING NOW.

To be excluded from the Class, Class Members may visit www.virginiamasonprivacyclassaction.com for instructions or call toll-free 1-844-609-1124. Class Members must mail their exclusion request postmarked by October 30, 2023. If Class Members exclude themselves, they cannot get any money or benefits from the lawsuit, but they will not be bound by any orders or judgments in the case. If Class Members do not request exclusion, they may (but do not have to) enter an appearance in the Court through their own counsel. The Court has appointed Terrell Marshall Law Group PLLC, Simmons Hanly Conroy, LLC, the Gorny Law Firm LC, Kiesel Law LLP, and the Simon Law Firm, PC as Class counsel. Detailed information is available at www.virginiamasonprivacyclassaction.com and toll-free at 1-844-609-1124. Class Members should not call Virginia Mason personnel, its counsel, or any Virginia Mason agent about this case.

/PRESS CONTACT: Notice Administrator
/URL: www.virginiamasonprivacyclassaction.com
/SOURCE: Superior Court for the State of Washington in and for the County of King

SOURCE Superior Court for the State of Washington in and for the County of King


These press releases may also interest you

14 fév 2025
Report with market evolution powered by AI - The global gender reassignment surgery market  size is estimated to grow by USD 374.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over 11.2%  during the...

14 fév 2025
On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the...

14 fév 2025
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase inhibitor, for adult patients with symptomatic...

14 fév 2025
We are accelerating Canada's work to detect, disrupt, and dismantle the fentanyl trade. Illegal drugs are having a devastating impact on people and communities, including creating security challenges associated with their illegal production,...

14 fév 2025
Aurora Cannabis Inc. (the "Company" or "Aurora")  , the Canadian-based leading global medical cannabis company, in conjunction with MedReleaf Australia, recently removed the concession card requirement for patients to access medical cannabis...

14 fév 2025
OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the "Company")) and OSR Holdings Co., Ltd. ("OSR") announced today the completion of their business combination (the "Business Combination")....



News published on and distributed by: